Longeveron to Participate in Three Longevity/Aging Investment Conferences
Globe Newswire (Wed, 30-Sep 4:05 PM ET)
Globe Newswire (Wed, 16-Sep 5:27 PM ET)
Longeveron to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Globe Newswire (Thu, 3-Sep 9:15 AM ET)
Longeveron Announces 1-for-10 Reverse Stock Split
Globe Newswire (Mon, 24-Aug 4:05 PM ET)
Longeveron Appoints Nirav Jhaveri as Chief Financial Officer
Globe Newswire (Wed, 19-Aug 4:05 PM ET)
Longeveron Announces 2026 Second Quarter Financial Results and Provides Business Update
Globe Newswire (Wed, 12-Aug 4:05 PM ET)
Globe Newswire (Tue, 11-Aug 9:05 AM ET)
Globe Newswire (Mon, 3-Aug 4:05 PM ET)
Deborah D. Ascheim, M.D. Elected to Longeveron Board of Directors
Globe Newswire (Thu, 23-Jul 9:15 AM ET)
Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.
Longeveron - Class A trades on the NASDAQ stock market under the symbol LGVN.
As of October 13, 2026, LGVN stock price declined to $2.15 with 60,133 million shares trading.
LGVN has a beta of 1.20, meaning it tends to be more sensitive to market movements. LGVN has a correlation of 0.01 to the broad based SPY ETF.
LGVN has a market cap of $6.85 million. This is considered a Sub-Micro Cap stock.
Last quarter Longeveron - Class A reported $287,000 in Revenue and -$1.90 earnings per share. This fell short of revenue expectation by $-39,800 and met earnings estimates .
In the last 3 years, LGVN traded as high as $239.00 and as low as $2.14.
The top ETF exchange traded funds that LGVN belongs to (by Net Assets): VXF, VTI.
LGVN has underperformed the market in the last year with a price return of -73.5% while the SPY ETF gained +20.3%. LGVN has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -68.1% and -18.3%, respectively, while the SPY returned +3.3% and +1.6%, respectively.
LGVN support price is $2.28 and resistance is $2.62 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LGVN shares will trade within this expected range on the day.
